|
Dr. Johnson was most recently with Cambridge Antibody Technologies, one of Europe’s most successful biotech companies, where he was a member of the start-up team, Chief Technology Officer and Member of the Board. He led the team that produced Humira, the first fully human therapeutic antibody and was part of the management team that floated CAT plc on the London Stock Exchange in 1997. Dr. Johnson’s other notable achievements include managing the discovery and development of a further four drugs in phase II-III clinical development. Kevin graduated in Molecular Biology from Edinburgh University and has a PhD in Pathology from Cambridge University. Kevin is a Venture Partner with Index Ventures based in London, UK and a General Partner in Ash Biotech Consulting, a leading consultancy company based in Cambridge, UK. | 